{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:31:37Z","timestamp":1791491497152,"version":"4.3.4"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12026-025-09606-9","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:09:30Z","timestamp":1741694970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Systemic barrier dysfunction in type 2 inflammation diseases: perspective in the skin, airways, and gastrointestinal tract"],"prefix":"10.1007","volume":"73","author":[{"given":"Juan","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueke","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuntao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"1","key":"9606_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. https:\/\/doi.org\/10.1038\/s41572-018-0001-z.","journal-title":"Nat Rev Dis Primers"},{"key":"9606_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.08.017","author":"B Kim","year":"2023","unstructured":"Kim B, Rothenberg ME, Sun X, Bachert C, Artis D, Zaheer R, et al. Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms, and therapeutic targets in atopic diseases. J Allergy Clin Immunol. 2023. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.017.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"9606_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2567.2011.03413.x","volume":"132","author":"S Koyasu","year":"2011","unstructured":"Koyasu S, Moro K. Type 2 innate immune responses and the natural helper cell. Immunology. 2011;132(4):475\u201381. https:\/\/doi.org\/10.1111\/j.1365-2567.2011.03413.x.","journal-title":"Immunology"},{"key":"9606_CR4","unstructured":"Prescott J, Szeszko A. The emerging role of the type 2 inflammatory cascade in atopic diseases[J]. 2019."},{"key":"9606_CR5","unstructured":"Kenneth M, Casey W. Janeway's immuno biology 9th edition [M]. Taylor & Francis Group, LLC, Garland Science; 2017."},{"issue":"6","key":"9606_CR6","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jaci.2017.04.010","volume":"139","author":"RP Schleimer","year":"2017","unstructured":"Schleimer RP, Berdnikovs S. Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases. J Allergy Clin Immunol. 2017;139(6):1752\u201361. https:\/\/doi.org\/10.1016\/j.jaci.2017.04.010.","journal-title":"J Allergy Clin Immunol"},{"key":"9606_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coi.2019.11.004","volume":"62","author":"SB Larsen","year":"2020","unstructured":"Larsen SB, Cowley CJ, Fuchs E. Epithelial cells: liaisons of immunity. Curr Opin Immunol. 2020;62:45\u201353. https:\/\/doi.org\/10.1016\/j.coi.2019.11.004.","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"9606_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jaci.2014.05.049","volume":"134","author":"SN Georas","year":"2014","unstructured":"Georas SN, Rezaee F. Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation. J Allergy Clin Immunol. 2014;134(3):509\u201320. https:\/\/doi.org\/10.1016\/j.jaci.2014.05.049.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"9606_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.18176\/jiaci.0779","volume":"32","author":"E Izquierdo","year":"2022","unstructured":"Izquierdo E, Rodriguez-Coira J, Delgado-Dolset MI, Gomez-Casado C, Barber D, Escribese MM. Epithelial barrier: protector and trigger of allergic disorders. J Investig Allergol Clin Immunol. 2022;32(2):81\u201396. https:\/\/doi.org\/10.18176\/jiaci.0779.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"9606_CR10","doi-asserted-by":"publisher","first-page":"C1213","DOI":"10.1152\/ajpcell.00558.2003","volume":"286","author":"EE Schneeberger","year":"2004","unstructured":"Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol. 2004;286(6):C1213\u201328. https:\/\/doi.org\/10.1152\/ajpcell.00558.2003.","journal-title":"Am J Physiol Cell Physiol"},{"key":"9606_CR11","doi-asserted-by":"publisher","first-page":"1093800","DOI":"10.3389\/falgy.2023.1093800","volume":"4","author":"J Parron-Ballesteros","year":"2023","unstructured":"Parron-Ballesteros J, Gordo RG, Lopez-Rodriguez JC, Olmo N, Villalba M, Batanero E, et al. Beyond allergic progression: from molecules to microbes as barrier modulators in the gut-lung axis functionality. Front Allergy. 2023;4:1093800. https:\/\/doi.org\/10.3389\/falgy.2023.1093800.","journal-title":"Front Allergy"},{"issue":"2","key":"9606_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","volume":"135","author":"S Noda","year":"2015","unstructured":"Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324\u201336. https:\/\/doi.org\/10.1016\/j.jaci.2014.11.015.","journal-title":"J Allergy Clin Immunol"},{"key":"9606_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.08.017","author":"B Kim","year":"2023","unstructured":"Kim B, Rothenberg ME, Sun X, Bachert C, Artis D, Zaheer R, et al. Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic targets in atopic diseases. J Allergy Clin Immunol. 2023. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.017.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"9606_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy SM. Tezepelumab: first approval. Drugs. 2022;82(4):461\u20138. https:\/\/doi.org\/10.1007\/s40265-022-01679-2.","journal-title":"Drugs"},{"issue":"11","key":"9606_CR15","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41577-021-00538-7","volume":"21","author":"CA Akdis","year":"2021","unstructured":"Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021;21(11):739\u201351. https:\/\/doi.org\/10.1038\/s41577-021-00538-7.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"9606_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.18176\/jiaci.0603","volume":"31","author":"JC Lopez-Rodriguez","year":"2021","unstructured":"Lopez-Rodriguez JC, Gonzalez M, Bogas G, Mayorga C, Villalba M, Batanero E. Epithelial permeability to Ole e 1 is more dependent on the functional state of the bronchial epithelium than on the activity of Der p 1 protease acting as an adjuvant to the bystander allergen. J Investig Allergol Clin Immunol. 2021;31(4):343\u20136. https:\/\/doi.org\/10.18176\/jiaci.0603.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"12","key":"9606_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1164\/rccm.200801-136OC","volume":"178","author":"U Sajjan","year":"2008","unstructured":"Sajjan U, Wang Q, Zhao Y, Gruenert DC, Hershenson MB. Rhinovirus disrupts the barrier function of polarized airway epithelial cells. Am J Respir Crit Care Med. 2008;178(12):1271\u201381. https:\/\/doi.org\/10.1164\/rccm.200801-136OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"9606_CR18","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/all.13763","volume":"74","author":"T Haahtela","year":"2019","unstructured":"Haahtela T. A biodiversity hypothesis. Allergy. 2019;74(8):1445\u201356. https:\/\/doi.org\/10.1111\/all.13763.","journal-title":"Allergy"},{"issue":"2","key":"9606_CR19","doi-asserted-by":"publisher","first-page":"e0147809","DOI":"10.1371\/journal.pone.0147809","volume":"11","author":"A Hevia","year":"2016","unstructured":"Hevia A, Milani C, Lopez P, Donado CD, Cuervo A, Gonzalez S, et al. Allergic patients with long-term asthma display low levels of Bifidobacterium adolescentis. PLoS ONE. 2016;11(2):e0147809. https:\/\/doi.org\/10.1371\/journal.pone.0147809.","journal-title":"PLoS ONE"},{"issue":"3","key":"9606_CR20","doi-asserted-by":"publisher","first-page":"e1341367","DOI":"10.1080\/21688370.2017.1341367","volume":"5","author":"KL Pothoven","year":"2017","unstructured":"Pothoven KL, Schleimer RP. The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease. Tissue Barriers. 2017;5(3):e1341367. https:\/\/doi.org\/10.1080\/21688370.2017.1341367.","journal-title":"Tissue Barriers"},{"issue":"3","key":"9606_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.jaci.2016.07.003","volume":"138","author":"M Xian","year":"2016","unstructured":"Xian M, Wawrzyniak P, Ruckert B, Duan S, Meng Y, Sokolowska M, et al. Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes. J Allergy Clin Immunol. 2016;138(3):890-3 e9. https:\/\/doi.org\/10.1016\/j.jaci.2016.07.003.","journal-title":"J Allergy Clin Immunol."},{"issue":"5","key":"9606_CR22","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.jaci.2018.11.016","volume":"143","author":"M Wang","year":"2019","unstructured":"Wang M, Tan G, Eljaszewicz A, Meng Y, Wawrzyniak P, Acharya S, et al. Laundry detergents and detergent residue after rinsing directly disrupt tight junction barrier integrity in human bronchial epithelial cells. J Allergy Clin Immunol. 2019;143(5):1892\u2013903. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.016.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"9606_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jaci.2022.10.020","volume":"151","author":"I Ogulur","year":"2023","unstructured":"Ogulur I, Pat Y, Aydin T, Yazici D, Ruckert B, Peng Y, et al. Gut epithelial barrier damage caused by dishwasher detergents and rinse aids. J Allergy Clin Immunol. 2023;151(2):469\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2022.10.020.","journal-title":"J Allergy Clin Immunol"},{"key":"9606_CR24","doi-asserted-by":"publisher","unstructured":"Sandall AM, Cox SR, Lindsay JO, Gewirtz AT, Chassaing B, Rossi M, et al. Emulsifiers impact colonic length in mice and emulsifier restriction is feasible in people with Crohn\u2019s disease. Nutrients. 2020;12(9). https:\/\/doi.org\/10.3390\/nu12092827.","DOI":"10.3390\/nu12092827"},{"issue":"1","key":"9606_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/apt.15045","volume":"49","author":"EP Halmos","year":"2019","unstructured":"Halmos EP, Mack A, Gibson PR. Review article: Emulsifiers in the food supply and implications for gastrointestinal disease. Aliment Pharmacol Ther. 2019;49(1):41\u201350. https:\/\/doi.org\/10.1111\/apt.15045.","journal-title":"Aliment Pharmacol Ther"},{"key":"9606_CR26","doi-asserted-by":"publisher","first-page":"887672","DOI":"10.3389\/falgy.2022.887672","volume":"3","author":"Z Celebi Sozener","year":"2022","unstructured":"Celebi Sozener Z, Ozbey Yucel U, Altiner S, Ozdel Ozturk B, Cerci P, Turk M, et al. The external exposome and allergies: from the perspective of the epithelial barrier hypothesis. Front Allergy. 2022;3:887672. https:\/\/doi.org\/10.3389\/falgy.2022.887672.","journal-title":"Front Allergy"},{"issue":"7","key":"9606_CR27","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/all.14318","volume":"75","author":"CA Akdis","year":"2020","unstructured":"Akdis CA, Arkwright PD, Bruggen MC, Busse W, Gadina M, Guttman-Yassky E, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582\u2013605. https:\/\/doi.org\/10.1111\/all.14318.","journal-title":"Allergy"},{"issue":"1","key":"9606_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1089\/ped.2019.1109","volume":"33","author":"RJ Hopp","year":"2020","unstructured":"Hopp RJ. Hypersensitivity reactions: an everyday occurrence in pediatric allergy clinics. Pediatr Allergy Immunol Pulmonol. 2020;33(1):12\u20138. https:\/\/doi.org\/10.1089\/ped.2019.1109.","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"3","key":"9606_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","volume":"135","author":"F Annunziato","year":"2015","unstructured":"Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626\u201335. https:\/\/doi.org\/10.1016\/j.jaci.2014.11.001.","journal-title":"J Allergy Clin Immunol"},{"key":"9606_CR30","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.3389\/fimmu.2019.02507","volume":"10","author":"C Egholm","year":"2019","unstructured":"Egholm C, Heeb LEM, Impellizzieri D, Boyman O. The regulatory effects of interleukin-4 receptor signaling on neutrophils in type 2 immune responses. Front Immunol. 2019;10:2507. https:\/\/doi.org\/10.3389\/fimmu.2019.02507.","journal-title":"Front Immunol"},{"key":"9606_CR31","doi-asserted-by":"publisher","unstructured":"Lloyd CM, Snelgrove RJ. Type 2 immunity: expanding our view. Sci Immunol. 2018;3(25). https:\/\/doi.org\/10.1126\/sciimmunol.aat1604.","DOI":"10.1126\/sciimmunol.aat1604"},{"issue":"6","key":"9606_CR32","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s41385-022-00557-0","volume":"15","author":"F Hartung","year":"2022","unstructured":"Hartung F, Esser-von BJ. Trained immunity in type 2 immune responses. Mucosal Immunol. 2022;15(6):1158\u201369. https:\/\/doi.org\/10.1038\/s41385-022-00557-0.","journal-title":"Mucosal Immunol"},{"issue":"7","key":"9606_CR33","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/cea.13954","volume":"51","author":"JD Hamilton","year":"2021","unstructured":"Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915\u201331. https:\/\/doi.org\/10.1111\/cea.13954.","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"9606_CR34","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.immuni.2014.09.006","volume":"41","author":"ANJ McKenzie","year":"2014","unstructured":"McKenzie ANJ, Spits H, Eberl G. Innate lymphoid cells in inflammation and immunity. Immunity. 2014;41(3):366\u201374. https:\/\/doi.org\/10.1016\/j.immuni.2014.09.006.","journal-title":"Immunity"},{"issue":"2","key":"9606_CR35","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/eji.201242863","volume":"43","author":"CS Hardman","year":"2013","unstructured":"Hardman CS, Panova V, McKenzie AN. IL-33 citrine reporter mice reveal the temporal and spatial expression of IL-33 during allergic lung inflammation. Eur J Immunol. 2013;43(2):488\u201398. https:\/\/doi.org\/10.1002\/eji.201242863.","journal-title":"Eur J Immunol"},{"issue":"7585","key":"9606_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature16161","volume":"529","author":"J von Moltke","year":"2016","unstructured":"von Moltke J, Ji M, Liang HE, Locksley RM. Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. Nature. 2016;529(7585):221\u20135. https:\/\/doi.org\/10.1038\/nature16161.","journal-title":"Nature"},{"issue":"7470","key":"9606_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nature12526","volume":"502","author":"JC Nussbaum","year":"2013","unstructured":"Nussbaum JC, Van Dyken SJ, von Moltke J, Cheng LE, Mohapatra A, Molofsky AB, et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature. 2013;502(7470):245\u20138. https:\/\/doi.org\/10.1038\/nature12526.","journal-title":"Nature"},{"issue":"1","key":"9606_CR38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaci.2017.02.038","volume":"141","author":"K Sugita","year":"2018","unstructured":"Sugita K, Steer CA, Martinez-Gonzalez I, Altunbulakli C, Morita H, Castro-Giner F, et al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):300-10 e11. https:\/\/doi.org\/10.1016\/j.jaci.2017.02.038.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"9606_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.immuni.2023.03.015","volume":"56","author":"EB Kopp","year":"2023","unstructured":"Kopp EB, Agaronyan K, Licona-Limon I, Nish SA, Medzhitov R. Modes of type 2 immune response initiation. Immunity. 2023;56(4):687\u201394. https:\/\/doi.org\/10.1016\/j.immuni.2023.03.015.","journal-title":"Immunity"},{"key":"9606_CR40","doi-asserted-by":"publisher","unstructured":"Iwaszko M, Bialy S, Bogunia-Kubik K. Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis. Cells. 2021;10(11). https:\/\/doi.org\/10.3390\/cells10113000.","DOI":"10.3390\/cells10113000"},{"issue":"1","key":"9606_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350. https:\/\/doi.org\/10.1038\/nrd4624.","journal-title":"Nat Rev Drug Discov"},{"key":"9606_CR42","doi-asserted-by":"publisher","unstructured":"Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003;111(4):677\u201390; quiz 91. https:\/\/doi.org\/10.1067\/mai.2003.1333.","DOI":"10.1067\/mai.2003.1333"},{"issue":"6","key":"9606_CR43","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/s41418-023-01155-8","volume":"30","author":"L Qin","year":"2023","unstructured":"Qin L, Song Y, Zhang F, Wang R, Zhou L, Jin S, et al. CRL4B complex-mediated H2AK119 monoubiquitination restrains Th1 and Th2 cell differentiation. Cell Death Differ. 2023;30(6):1488\u2013502. https:\/\/doi.org\/10.1038\/s41418-023-01155-8.","journal-title":"Cell Death Differ"},{"issue":"20","key":"9606_CR44","doi-asserted-by":"publisher","first-page":"10838","DOI":"10.1073\/pnas.94.20.10838","volume":"94","author":"N Noben-Trauth","year":"1997","unstructured":"Noben-Trauth N, Shultz LD, Brombacher F, Urban JF Jr, Gu H, Paul WE. An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc Natl Acad Sci U S A. 1997;94(20):10838\u201343. https:\/\/doi.org\/10.1073\/pnas.94.20.10838.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9606_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-immunol-032712-095906","volume":"31","author":"SJ Van Dyken","year":"2013","unstructured":"Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol. 2013;31:317\u201343. https:\/\/doi.org\/10.1146\/annurev-immunol-032712-095906.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"9606_CR46","doi-asserted-by":"publisher","first-page":"112471","DOI":"10.1016\/j.celrep.2023.112471","volume":"42","author":"B Dang","year":"2023","unstructured":"Dang B, Gao Q, Zhang L, Zhang J, Cai H, Zhu Y, et al. The glycolysis\/HIF-1alpha axis defines the inflammatory role of IL-4-primed macrophages. Cell Rep. 2023;42(5):112471. https:\/\/doi.org\/10.1016\/j.celrep.2023.112471.","journal-title":"Cell Rep"},{"key":"9606_CR47","doi-asserted-by":"publisher","unstructured":"Furue M. Regulation of skin barrier function via competition between AHR axis versus IL-13\/IL-4\u2012JAK\u2012STAT6\/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis. J Clin Med. 2020;9(11). https:\/\/doi.org\/10.3390\/jcm9113741.","DOI":"10.3390\/jcm9113741"},{"issue":"5","key":"9606_CR48","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.immuni.2020.04.008","volume":"52","author":"F Wang","year":"2020","unstructured":"Wang F, Kim BS. Itch: A paradigm of neuroimmune crosstalk. Immunity. 2020;52(5):753\u201366. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.008.","journal-title":"Immunity"},{"key":"9606_CR49","doi-asserted-by":"publisher","unstructured":"Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines (Basel). 2021;9(3). https:\/\/doi.org\/10.3390\/vaccines9030303.","DOI":"10.3390\/vaccines9030303"},{"issue":"5","key":"9606_CR50","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jaci.2018.09.011","volume":"142","author":"C Nassenstein","year":"2018","unstructured":"Nassenstein C, Krasteva-Christ G, Renz H. New aspects of neuroinflammation and neuroimmune crosstalk in the airways. J Allergy Clin Immunol. 2018;142(5):1415\u201322. https:\/\/doi.org\/10.1016\/j.jaci.2018.09.011.","journal-title":"J Allergy Clin Immunol"},{"key":"9606_CR51","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-pathol-012615-044241","volume":"11","author":"BP Davis","year":"2016","unstructured":"Davis BP, Rothenberg ME. Mechanisms of disease of eosinophilic esophagitis. Annu Rev Pathol. 2016;11:365\u201393. https:\/\/doi.org\/10.1146\/annurev-pathol-012615-044241.","journal-title":"Annu Rev Pathol"},{"issue":"6","key":"9606_CR52","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.4049\/jimmunol.171.6.3262","volume":"171","author":"I Nomura","year":"2003","unstructured":"Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol. 2003;171(6):3262\u20139. https:\/\/doi.org\/10.4049\/jimmunol.171.6.3262.","journal-title":"J Immunol"},{"issue":"12","key":"9606_CR53","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.4014\/jmb.2009.09019","volume":"30","author":"KH Sohn","year":"2020","unstructured":"Sohn KH, Baek MG, Choi SM, Bae B, Kim RY, Kim YC, et al. Alteration of lung and gut microbiota in IL-13-transgenic mice simulating chronic asthma. J Microbiol Biotechnol. 2020;30(12):1819\u201326. https:\/\/doi.org\/10.4014\/jmb.2009.09019.","journal-title":"J Microbiol Biotechnol"},{"issue":"6","key":"9606_CR54","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1540\/jsmr.39.221","volume":"39","author":"Y Chiba","year":"2003","unstructured":"Chiba Y, Sakai H, Wachi H, Sugitani H, Seyama Y, Misawa M. Upregulation of rhoA mRNA in bronchial smooth muscle of antigen-induced airway hyperresponsive rats. J Smooth Muscle Res. 2003;39(6):221\u20138. https:\/\/doi.org\/10.1540\/jsmr.39.221.","journal-title":"J Smooth Muscle Res"},{"issue":"2","key":"9606_CR55","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1165\/rcmb.2008-0162OC","volume":"40","author":"Y Chiba","year":"2009","unstructured":"Chiba Y, Nakazawa S, Todoroki M, Shinozaki K, Sakai H, Misawa M. Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein. Am J Respir Cell Mol Biol. 2009;40(2):159\u201367. https:\/\/doi.org\/10.1165\/rcmb.2008-0162OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"9606_CR56","doi-asserted-by":"publisher","unstructured":"Bros M, Haas K, Moll L, Grabbe S. RhoA as a key regulator of innate and adaptive immunity. Cells. 2019;8(7). https:\/\/doi.org\/10.3390\/cells8070733.","DOI":"10.3390\/cells8070733"},{"issue":"10","key":"9606_CR57","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/intimm\/10.10.1421","volume":"10","author":"C Doucet","year":"1998","unstructured":"Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Jasmin C, Canonica GW, Azzarone B. IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol. 1998;10(10):1421\u201333. https:\/\/doi.org\/10.1093\/intimm\/10.10.1421.","journal-title":"Int Immunol"},{"issue":"10","key":"9606_CR58","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1172\/JCI741","volume":"101","author":"C Doucet","year":"1998","unstructured":"Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts Implication in asthma. J Clin Invest. 1998;101(10):2129\u201339. https:\/\/doi.org\/10.1172\/JCI741.","journal-title":"J Clin Invest"},{"issue":"10","key":"9606_CR59","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.4049\/jimmunol.162.10.6233","volume":"162","author":"K Dabbagh","year":"1999","unstructured":"Dabbagh K, Takeyama K, Lee HM, Ueki IF, Lausier JA, Nadel JA. IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J Immunol. 1999;162(10):6233\u20137.","journal-title":"J Immunol"},{"issue":"6","key":"9606_CR60","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1172\/JCI84910","volume":"126","author":"LR Bonser","year":"2016","unstructured":"Bonser LR, Zlock L, Finkbeiner W, Erle DJ. Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma. J Clin Invest. 2016;126(6):2367\u201371. https:\/\/doi.org\/10.1172\/JCI84910.","journal-title":"J Clin Invest"},{"key":"9606_CR61","doi-asserted-by":"publisher","unstructured":"Busse WW, Kraft M, Rabe KF, Deniz Y, Rowe PJ, Ruddy M, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J. 2021;58(2). https:\/\/doi.org\/10.1183\/13993003.03393-2020.","DOI":"10.1183\/13993003.03393-2020"},{"key":"9606_CR62","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","volume":"12","author":"RP Schleimer","year":"2017","unstructured":"Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017;12:331\u201357. https:\/\/doi.org\/10.1146\/annurev-pathol-052016-100401.","journal-title":"Annu Rev Pathol"},{"issue":"10247","key":"9606_CR63","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"issue":"2","key":"9606_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"GG Brusselle","year":"2022","unstructured":"Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157\u201371. https:\/\/doi.org\/10.1056\/NEJMra2032506.","journal-title":"N Engl J Med"},{"issue":"11","key":"9606_CR65","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jid.2021.04.002","volume":"141","author":"X Dai","year":"2021","unstructured":"Dai X, Utsunomiya R, Shiraishi K, Mori H, Muto J, Murakami M, et al. Nuclear IL-33 plays an important role in the suppression of FLG, LOR, keratin 1, and keratin 10 by IL-4 and IL-13 in human keratinocytes. J Invest Dermatol. 2021;141(11):2646-55 e6. https:\/\/doi.org\/10.1016\/j.jid.2021.04.002.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"9606_CR66","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.4049\/jimmunol.1100504","volume":"186","author":"MH Oh","year":"2011","unstructured":"Oh MH, Oh SY, Yu J, Myers AC, Leonard WJ, Liu YJ, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol. 2011;186(12):7232\u201342. https:\/\/doi.org\/10.4049\/jimmunol.1100504.","journal-title":"J Immunol"},{"issue":"3","key":"9606_CR67","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0022-3565(24)35380-7","volume":"292","author":"A Oriente","year":"2000","unstructured":"Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther. 2000;292(3):988\u201394.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"9606_CR68","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0014-5793(92)80448-p","volume":"302","author":"P Gillery","year":"1992","unstructured":"Gillery P, Fertin C, Nicolas JF, Chastang F, Kalis B, Banchereau J, et al. Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis FEBS Lett. 1992;302(3):231\u20134. https:\/\/doi.org\/10.1016\/0014-5793(92)80448-p.","journal-title":"Potential role in fibrosis FEBS Lett"},{"issue":"4","key":"9606_CR69","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/jcm4040741","volume":"4","author":"A De Benedetto","year":"2015","unstructured":"De Benedetto A, Yoshida T, Fridy S, Park JE, Kuo IH, Beck LA. Histamine and skin barrier: are histamine antagonists useful for the prevention or treatment of atopic dermatitis? J Clin Med. 2015;4(4):741\u201355. https:\/\/doi.org\/10.3390\/jcm4040741.","journal-title":"J Clin Med"},{"issue":"5","key":"9606_CR70","doi-asserted-by":"publisher","first-page":"100131","DOI":"10.1016\/j.xjidi.2022.100131","volume":"2","author":"LA Beck","year":"2022","unstructured":"Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innov. 2022;2(5):100131. https:\/\/doi.org\/10.1016\/j.xjidi.2022.100131.","journal-title":"JID Innov"},{"issue":"4","key":"9606_CR71","doi-asserted-by":"publisher","first-page":"410","DOI":"10.5021\/ad.2013.25.4.410","volume":"25","author":"HY Park","year":"2013","unstructured":"Park HY, Kim CR, Huh IS, Jung MY, Seo EY, Park JH, et al. Staphylococcus aureus colonization in acute and chronic skin lesions of patients with atopic dermatitis. Ann Dermatol. 2013;25(4):410\u20136. https:\/\/doi.org\/10.5021\/ad.2013.25.4.410.","journal-title":"Ann Dermatol"},{"key":"9606_CR72","doi-asserted-by":"publisher","first-page":"718708","DOI":"10.1155\/2011\/718708","volume":"2011","author":"C Pascolini","year":"2011","unstructured":"Pascolini C, Sinagra J, Pecetta S, Bordignon V, De Santis A, Cilli L, et al. Molecular and immunological characterization of Staphylococcus aureus in pediatric atopic dermatitis: implications for prophylaxis and clinical management. Clin Dev Immunol. 2011;2011:718708. https:\/\/doi.org\/10.1155\/2011\/718708.","journal-title":"Clin Dev Immunol"},{"issue":"6","key":"9606_CR73","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/JLB.3MR0921-030RRR","volume":"110","author":"X Tian","year":"2021","unstructured":"Tian X, Huang Q, Liang J, Wang J, Zhang J, Yang Y, et al. A review of the mechanisms of keratinocytes damage caused by Staphylococcus aureus infection in patients with atopic dermatitis. J Leukoc Biol. 2021;110(6):1163\u20139. https:\/\/doi.org\/10.1002\/JLB.3MR0921-030RRR.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"9606_CR74","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5604\/17331331.1215600","volume":"65","author":"A Buda","year":"2016","unstructured":"Buda A, Miedzobrodzki J. The role of Staphylococcus aureus in secondary infections in patients with atopic dermatitis (AD). Pol J Microbiol. 2016;65(3):253\u20139. https:\/\/doi.org\/10.5604\/17331331.1215600.","journal-title":"Pol J Microbiol"},{"issue":"1","key":"9606_CR75","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-28 e13. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006.","journal-title":"Cell."},{"issue":"47","key":"9606_CR76","doi-asserted-by":"publisher","first-page":"E7572","DOI":"10.1073\/pnas.1606608113","volume":"113","author":"B Liu","year":"2016","unstructured":"Liu B, Tai Y, Achanta S, Kaelberer MM, Caceres AI, Shao X, et al. IL-33\/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy. Proc Natl Acad Sci U S A. 2016;113(47):E7572\u20139. https:\/\/doi.org\/10.1073\/pnas.1606608113.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 3","key":"9606_CR77","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1542\/peds.2014-1817VV","volume":"134","author":"TP Moran","year":"2014","unstructured":"Moran TP, Vickery BP. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Pediatrics. 2014;134(Suppl 3):S160-1. https:\/\/doi.org\/10.1542\/peds.2014-1817VV.","journal-title":"Pediatrics"},{"issue":"1","key":"9606_CR78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/ced.14380","volume":"46","author":"XQ Hu","year":"2021","unstructured":"Hu XQ, Tang Y, Ju Y, Zhang XY, Yan JJ, Wang CM, et al. Scratching damages tight junctions through the Akt-claudin 1 axis in atopic dermatitis. Clin Exp Dermatol. 2021;46(1):74\u201381. https:\/\/doi.org\/10.1111\/ced.14380.","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"9606_CR79","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1111\/1346-8138.16067","volume":"48","author":"T Satoh","year":"2021","unstructured":"Satoh T, Yokozeki H, Murota H, Tokura Y, Kabashima K, Takamori K, et al. 2020 guidelines for the diagnosis and treatment of prurigo. J Dermatol. 2021;48(9):e414\u201331. https:\/\/doi.org\/10.1111\/1346-8138.16067.","journal-title":"J Dermatol"},{"issue":"6","key":"9606_CR80","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2340\/00015555-3150","volume":"99","author":"W Zhong","year":"2019","unstructured":"Zhong W, Wu X, Zhang W, Zhang J, Chen X, Chen S, et al. Aberrant expression of histamine-independent pruritogenic mediators in keratinocytes may be involved in the pathogenesis of prurigo nodularis. Acta Derm Venereol. 2019;99(6):579\u201386. https:\/\/doi.org\/10.2340\/00015555-3150.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"9606_CR81","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/exd.14279","volume":"30","author":"T Hashimoto","year":"2021","unstructured":"Hashimoto T, Nattkemper LA, Kim HS, Kursewicz CD, Fowler E, Shah SM, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol. 2021;30(6):804\u201310. https:\/\/doi.org\/10.1111\/exd.14279.","journal-title":"Exp Dermatol"},{"issue":"1","key":"9606_CR82","doi-asserted-by":"publisher","first-page":"adv00375","DOI":"10.2340\/00015555-3702","volume":"101","author":"T Hashimoto","year":"2021","unstructured":"Hashimoto T, Nattkemper LA, Kim HS, Kursewicz CD, Fowler E, Shah SM, et al. Dermal periostin: a new player in itch of prurigo nodularis. Acta Derm Venereol. 2021;101(1):adv00375. https:\/\/doi.org\/10.2340\/00015555-3702.","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"9606_CR83","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1172\/JCI58978","volume":"122","author":"M Masuoka","year":"2012","unstructured":"Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122(7):2590\u2013600. https:\/\/doi.org\/10.1172\/JCI58978.","journal-title":"J Clin Invest"},{"key":"9606_CR84","unstructured":"Dabija D, Tadi P, Danosos GN. Chronic urticaria. 2023 Apr 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025."},{"issue":"3","key":"9606_CR85","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","volume":"128","author":"S Saini","year":"2011","unstructured":"Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567-73 e1. https:\/\/doi.org\/10.1016\/j.jaci.2011.06.010.","journal-title":"J Allergy Clin Immunol."},{"key":"9606_CR86","doi-asserted-by":"publisher","unstructured":"Brodell LA, Beck LA, Saini SS. Pathophysiology of chronic urticaria. Ann Allergy Asthma Immunol. 2008;100(4):291\u20137; quiz 7\u20139, 322. https:\/\/doi.org\/10.1016\/S1081-1206(10)60588-1.","DOI":"10.1016\/S1081-1206(10)60588-1"},{"issue":"1","key":"9606_CR87","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.iac.2013.09.012","volume":"34","author":"SS Saini","year":"2014","unstructured":"Saini SS. Chronic spontaneous urticaria: etiology and pathogenesis. Immunol Allergy Clin North Am. 2014;34(1):33\u201352. https:\/\/doi.org\/10.1016\/j.iac.2013.09.012.","journal-title":"Immunol Allergy Clin North Am"},{"key":"9606_CR88","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/5584_2020_612","volume":"1326","author":"M Folci","year":"2021","unstructured":"Folci M, Ramponi G, Brunetta E. A comprehensive approach to urticaria: from clinical presentation to modern biological treatments through pathogenesis. Adv Exp Med Biol. 2021;1326:111\u201337. https:\/\/doi.org\/10.1007\/5584_2020_612.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"9606_CR89","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00441-014-2061-z","volume":"360","author":"G Walko","year":"2015","unstructured":"Walko G, Castanon MJ, Wiche G. Molecular architecture and function of the hemidesmosome. Cell Tissue Res. 2015;360(2):363\u201378. https:\/\/doi.org\/10.1007\/s00441-014-2061-z.","journal-title":"Cell Tissue Res"},{"issue":"1","key":"9606_CR90","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/exd.12877","volume":"25","author":"K Kunzli","year":"2016","unstructured":"Kunzli K, Favre B, Chofflon M, Borradori L. One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1. Exp Dermatol. 2016;25(1):10\u20136. https:\/\/doi.org\/10.1111\/exd.12877.","journal-title":"Exp Dermatol"},{"issue":"4","key":"9606_CR91","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1365-2133.2001.04130.x","volume":"144","author":"E Laffitte","year":"2001","unstructured":"Laffitte E, Skaria M, Jaunin F, Tamm K, Saurat JH, Favre B, et al. Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses. Br J Dermatol. 2001;144(4):760\u20138. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04130.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"9606_CR92","first-page":"577","volume":"42","author":"R Dopp","year":"2000","unstructured":"Dopp R, Schmidt E, Chimanovitch I, Leverkus M, Brocker EB, Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol. 2000;42(4):577\u201383.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"9606_CR93","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jdv.14673","volume":"32","author":"K Eyerich","year":"2018","unstructured":"Eyerich K, Eyerich S. Immune response patterns in non-communicable inflammatory skin diseases. J Eur Acad Dermatol Venereol. 2018;32(5):692\u2013703. https:\/\/doi.org\/10.1111\/jdv.14673.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"9606_CR94","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","volume":"129","author":"H Iwata","year":"2009","unstructured":"Iwata H, Kamio N, Aoyama Y, Yamamoto Y, Hirako Y, Owaribe K, et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol. 2009;129(4):919\u201326. https:\/\/doi.org\/10.1038\/jid.2008.305.","journal-title":"J Invest Dermatol"},{"key":"9606_CR95","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.3389\/fimmu.2019.02331","volume":"10","author":"KN Messingham","year":"2019","unstructured":"Messingham KN, Crowe TP, Fairley JA. The intersection of IgE autoantibodies and eosinophilia in the pathogenesis of bullous pemphigoid. Front Immunol. 2019;10:2331. https:\/\/doi.org\/10.3389\/fimmu.2019.02331.","journal-title":"Front Immunol"},{"issue":"5","key":"9606_CR96","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/bjd.16679","volume":"179","author":"K Kridin","year":"2018","unstructured":"Kridin K. Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation. Br J Dermatol. 2018;179(5):1141\u20137. https:\/\/doi.org\/10.1111\/bjd.16679.","journal-title":"Br J Dermatol"},{"key":"9606_CR97","doi-asserted-by":"publisher","first-page":"156091","DOI":"10.1016\/j.cyto.2022.156091","volume":"162","author":"G Scott","year":"2023","unstructured":"Scott G, Asrat S, Allinne J, Keat Lim W, Nagashima K, Birchard D, et al. IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline. Cytokine. 2023;162:156091. https:\/\/doi.org\/10.1016\/j.cyto.2022.156091.","journal-title":"Cytokine"},{"issue":"5","key":"9606_CR98","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337. https:\/\/doi.org\/10.1080\/1744666X.2017.1298443.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"9606_CR99","doi-asserted-by":"publisher","first-page":"e24333","DOI":"10.4161\/tisb.24333","volume":"1","author":"B Saatian","year":"2013","unstructured":"Saatian B, Rezaee F, Desando S, Emo J, Chapman T, Knowlden S, et al. Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells. Tissue Barriers. 2013;1(2):e24333. https:\/\/doi.org\/10.4161\/tisb.24333.","journal-title":"Tissue Barriers"},{"issue":"1","key":"9606_CR100","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaci.2016.02.035","volume":"139","author":"K Sweerus","year":"2017","unstructured":"Sweerus K, Lachowicz-Scroggins M, Gordon E, LaFemina M, Huang X, Parikh M, et al. Claudin-18 deficiency is associated with airway epithelial barrier dysfunction and asthma. J Allergy Clin Immunol. 2017;139(1):72-81 e1. https:\/\/doi.org\/10.1016\/j.jaci.2016.02.035.","journal-title":"J Allergy Clin Immunol."},{"issue":"5","key":"9606_CR101","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/CM9.0000000000001983","volume":"135","author":"X Dong","year":"2022","unstructured":"Dong X, Ding M, Zhang J, Ogulur I, Pat Y, Akdis M, et al. Involvement and therapeutic implications of airway epithelial barrier dysfunction in type 2 inflammation of asthma. Chin Med J (Engl). 2022;135(5):519\u201331. https:\/\/doi.org\/10.1097\/CM9.0000000000001983.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"9606_CR102","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.otc.2016.08.004","volume":"50","author":"TW Vickery","year":"2017","unstructured":"Vickery TW, Ramakrishnan VR. Bacterial pathogens and the microbiome. Otolaryngol Clin North Am. 2017;50(1):29\u201347. https:\/\/doi.org\/10.1016\/j.otc.2016.08.004.","journal-title":"Otolaryngol Clin North Am"},{"key":"9606_CR103","doi-asserted-by":"publisher","DOI":"10.1111\/all.16064","author":"ZQ Huang","year":"2024","unstructured":"Huang ZQ, Liu J, Sun LY, Ong HH, Ye J, Xu Y, et al. Updated epithelial barrier dysfunction in chronic rhinosinusitis: targeting pathophysiology and treatment response of tight junctions. Allergy. 2024. https:\/\/doi.org\/10.1111\/all.16064.","journal-title":"Allergy"},{"issue":"3","key":"9606_CR104","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jaci.2020.01.027","volume":"145","author":"T Takabayashi","year":"2020","unstructured":"Takabayashi T, Schleimer RP. Formation of nasal polyps: the roles of innate type 2 inflammation and deposition of fibrin. J Allergy Clin Immunol. 2020;145(3):740\u201350. https:\/\/doi.org\/10.1016\/j.jaci.2020.01.027.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"9606_CR105","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/alr.21298","volume":"4","author":"SK Wise","year":"2014","unstructured":"Wise SK, Laury AM, Katz EH, Den Beste KA, Parkos CA, Nusrat A. Interleukin-4 and interleukin-13 compromise the sinonasal epithelial barrier and perturb intercellular junction protein expression. Int Forum Allergy Rhinol. 2014;4(5):361\u201370. https:\/\/doi.org\/10.1002\/alr.21298.","journal-title":"Int Forum Allergy Rhinol"},{"key":"9606_CR106","doi-asserted-by":"publisher","unstructured":"Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989\u201395 e1\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2011.07.056.","DOI":"10.1016\/j.jaci.2011.07.056"},{"key":"9606_CR107","doi-asserted-by":"publisher","unstructured":"Pelaia C, Pelaia G, Maglio A, Tinello C, Gallelli L, Lombardo N, et al. Pathobiology of type 2 inflammation in asthma and nasal polyposis. J Clin Med. 2023;12(10). https:\/\/doi.org\/10.3390\/jcm12103371.","DOI":"10.3390\/jcm12103371"},{"issue":"2","key":"9606_CR108","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.alit.2014.12.006","volume":"64","author":"A Kato","year":"2015","unstructured":"Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015;64(2):121\u201330. https:\/\/doi.org\/10.1016\/j.alit.2014.12.006.","journal-title":"Allergol Int"},{"issue":"9","key":"9606_CR109","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/cea.12780","volume":"46","author":"AO Eifan","year":"2016","unstructured":"Eifan AO, Durham SR. Pathogenesis of rhinitis. Clin Exp Allergy. 2016;46(9):1139\u201351. https:\/\/doi.org\/10.1111\/cea.12780.","journal-title":"Clin Exp Allergy"},{"key":"9606_CR110","doi-asserted-by":"publisher","unstructured":"Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado CA, Colodenco FD, Giavina-Bianchi P, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3). https:\/\/doi.org\/10.1183\/23120541.00576-2021.","DOI":"10.1183\/23120541.00576-2021"},{"issue":"5","key":"9606_CR111","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.jaci.2019.04.027","volume":"144","author":"B Steelant","year":"2019","unstructured":"Steelant B, Wawrzyniak P, Martens K, Jonckheere AC, Pugin B, Schrijvers R, et al. Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis. J Allergy Clin Immunol. 2019;144(5):1242-53 e7. https:\/\/doi.org\/10.1016\/j.jaci.2019.04.027.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"9606_CR112","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1053\/j.gastro.2017.06.065","volume":"154","author":"KM O'Shea","year":"2018","unstructured":"O\u2019Shea KM, Aceves SS, Dellon ES, Gupta SK, Spergel JM, Furuta GT, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology. 2018;154(2):333\u201345. https:\/\/doi.org\/10.1053\/j.gastro.2017.06.065.","journal-title":"Gastroenterology"},{"key":"9606_CR113","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1038\/ncomms6593","volume":"5","author":"PM Sleiman","year":"2014","unstructured":"Sleiman PM, Wang ML, Cianferoni A, Aceves S, Gonsalves N, Nadeau K, et al. GWAS identifies four novel eosinophilic esophagitis loci. Nat Commun. 2014;5:5593. https:\/\/doi.org\/10.1038\/ncomms6593.","journal-title":"Nat Commun"},{"issue":"4","key":"9606_CR114","doi-asserted-by":"publisher","first-page":"e86355","DOI":"10.1172\/jci.insight.86355","volume":"1","author":"BP Davis","year":"2016","unstructured":"Davis BP, Stucke EM, Khorki ME, Litosh VA, Rymer JK, Rochman M, et al. Eosinophilic esophagitis-linked calpain 14 is an IL-13-induced protease that mediates esophageal epithelial barrier impairment. JCI Insight. 2016;1(4):e86355. https:\/\/doi.org\/10.1172\/jci.insight.86355.","journal-title":"JCI Insight"},{"key":"9606_CR115","doi-asserted-by":"publisher","first-page":"815842","DOI":"10.3389\/fphys.2021.815842","volume":"12","author":"F Racca","year":"2021","unstructured":"Racca F, Pellegatta G, Cataldo G, Vespa E, Carlani E, Pelaia C, et al. Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets. Front Physiol. 2021;12:815842. https:\/\/doi.org\/10.3389\/fphys.2021.815842.","journal-title":"Front Physiol"},{"issue":"3","key":"9606_CR116","doi-asserted-by":"publisher","first-page":"G341","DOI":"10.1152\/ajpgi.00404.2017","volume":"315","author":"L Wu","year":"2018","unstructured":"Wu L, Oshima T, Li M, Tomita T, Fukui H, Watari J, et al. Filaggrin and tight junction proteins are crucial for IL-13-mediated esophageal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol. 2018;315(3):G341\u201350. https:\/\/doi.org\/10.1152\/ajpgi.00404.2017.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"9606_CR117","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.autrev.2012.12.002","volume":"12","author":"LP Seguro","year":"2013","unstructured":"Seguro LP, Rosario C, Shoenfeld Y. Long-term complications of past glucocorticoid use. Autoimmun Rev. 2013;12(5):629\u201332. https:\/\/doi.org\/10.1016\/j.autrev.2012.12.002.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"9606_CR118","doi-asserted-by":"publisher","first-page":"e41278","DOI":"10.7759\/cureus.41278","volume":"15","author":"SM Saad-Omer","year":"2023","unstructured":"Saad-Omer SM, Kinaan M, Matos M, Yao H. Exogenous cushing syndrome and hip fracture due to over-the-counter supplement (Artri King). Cureus. 2023;15(7):e41278. https:\/\/doi.org\/10.7759\/cureus.41278.","journal-title":"Cureus"},{"issue":"6","key":"9606_CR119","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2796.1994.tb00855.x","volume":"236","author":"HO Conn","year":"1994","unstructured":"Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236(6):619\u201332. https:\/\/doi.org\/10.1111\/j.1365-2796.1994.tb00855.x.","journal-title":"J Intern Med"},{"issue":"10","key":"9606_CR120","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1176\/appi.ajp.2014.13091264","volume":"171","author":"LL Judd","year":"2014","unstructured":"Judd LL, Schettler PJ, Brown ES, Wolkowitz OM, Sternberg EM, Bender BG, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014;171(10):1045\u201351. https:\/\/doi.org\/10.1176\/appi.ajp.2014.13091264.","journal-title":"Am J Psychiatry"},{"key":"9606_CR121","unstructured":"GINA. Diagnosis and management of difficult\u2010to\u2010treat and severe asthma in adolescent and adult patients[EB\/OL]. https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/04\/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf."},{"issue":"2","key":"9606_CR122","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jaci.2003.12.007","volume":"113","author":"D Hijnen","year":"2004","unstructured":"Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol. 2004;113(2):334\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2003.12.007.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"9606_CR123","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174-90 e1. https:\/\/doi.org\/10.1016\/j.jaci.2021.01.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"9606_CR124","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1111\/all.15089","volume":"76","author":"I Ogulur","year":"2021","unstructured":"Ogulur I, Pat Y, Ardicli O, Barletta E, Cevhertas L, Fernandez-Santamaria R, et al. Advances and highlights in biomarkers of allergic diseases. Allergy. 2021;76(12):3659\u201386. https:\/\/doi.org\/10.1111\/all.15089.","journal-title":"Allergy"},{"issue":"4","key":"9606_CR125","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","volume":"144","author":"AB Pavel","year":"2019","unstructured":"Pavel AB, Song T, Kim HJ, Del Duca E, Krueger JG, Dubin C, et al. Oral Janus kinase\/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(4):1011\u201324. https:\/\/doi.org\/10.1016\/j.jaci.2019.07.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"9606_CR126","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/jdv.15301","volume":"33","author":"K Clarysse","year":"2019","unstructured":"Clarysse K, Pfaff CM, Marquardt Y, Huth L, Kortekaas Krohn I, Kluwig D, et al. JAK1\/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis. J Eur Acad Dermatol Venereol. 2019;33(2):367\u201375. https:\/\/doi.org\/10.1111\/jdv.15301.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"9606_CR127","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349. https:\/\/doi.org\/10.1111\/bjd.19574.","journal-title":"Br J Dermatol"},{"issue":"5","key":"9606_CR128","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/17512433.2018.1449642","volume":"11","author":"M Seegraber","year":"2018","unstructured":"Seegraber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467\u201374. https:\/\/doi.org\/10.1080\/17512433.2018.1449642.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"9606_CR129","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1080\/09546634.2020.1853024","volume":"33","author":"H Husein-ElAhmed","year":"2022","unstructured":"Husein-ElAhmed H, Steinhoff M. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. J Dermatolog Treat. 2022;33(3):1547\u201353. https:\/\/doi.org\/10.1080\/09546634.2020.1853024.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"9606_CR130","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40265-020-01298-9","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy SM. Dupilumab: a review in chronic rhinosinusitis with nasal polyps. Drugs. 2020;80(7):711\u20137. https:\/\/doi.org\/10.1007\/s40265-020-01298-9.","journal-title":"Drugs"},{"issue":"4","key":"9606_CR131","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/phar.2783","volume":"43","author":"PD Meek","year":"2023","unstructured":"Meek PD, Hemstreet B. Emerging therapies for eosinophilic esophagitis. Pharmacotherapy. 2023;43(4):338\u201348. https:\/\/doi.org\/10.1002\/phar.2783.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"9606_CR132","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1314768.","journal-title":"N Engl J Med"},{"issue":"6","key":"9606_CR133","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","volume":"134","author":"JD Hamilton","year":"2014","unstructured":"Hamilton JD, Suarez-Farinas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293\u2013300. https:\/\/doi.org\/10.1016\/j.jaci.2014.10.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"9606_CR134","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, Suarez-Farinas M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155\u201372. https:\/\/doi.org\/10.1016\/j.jaci.2018.08.022.","journal-title":"J Allergy Clin Immunol"},{"key":"9606_CR135","doi-asserted-by":"publisher","unstructured":"Ishitsuka Y, Roop DR. Loricrin: past, present, and future. Int J Mol Sci. 2020;21(7). https:\/\/doi.org\/10.3390\/ijms21072271.","DOI":"10.3390\/ijms21072271"},{"issue":"1","key":"9606_CR136","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jid.2019.07.680","volume":"140","author":"T Bieber","year":"2020","unstructured":"Bieber T. Targeting T2 inflammation by dupilumab impacts on the microbiomic \u201cmenage a trois\u201d of atopic dermatitis. J Invest Dermatol. 2020;140(1):15\u20137. https:\/\/doi.org\/10.1016\/j.jid.2019.07.680.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"9606_CR137","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/all.14664","volume":"76","author":"MH Rohner","year":"2021","unstructured":"Rohner MH, Thormann K, Cazzaniga S, Yousefi S, Simon HU, Schlapbach C, et al. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. Allergy. 2021;76(4):1268\u201370. https:\/\/doi.org\/10.1111\/all.14664.","journal-title":"Allergy"},{"issue":"1S","key":"9606_CR138","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1097\/DER.0000000000000764","volume":"32","author":"D Mikhaylov","year":"2021","unstructured":"Mikhaylov D, Del Duca E, Olesen CM, He H, Wu J, Ungar B, et al. Transcriptomic profiling of tape-strips from moderate to severe atopic dermatitis patients treated with dupilumab. Dermatitis. 2021;32(1S):S71\u201380. https:\/\/doi.org\/10.1097\/DER.0000000000000764.","journal-title":"Dermatitis"},{"issue":"1","key":"9606_CR139","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaci.2020.06.012","volume":"147","author":"L Mobus","year":"2021","unstructured":"Mobus L, Rodriguez E, Harder I, Stolzl D, Boraczynski N, Gerdes S, et al. Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J Allergy Clin Immunol. 2021;147(1):213\u201323. https:\/\/doi.org\/10.1016\/j.jaci.2020.06.012.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"9606_CR140","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1111\/all.15432","volume":"77","author":"E Berdyshev","year":"2022","unstructured":"Berdyshev E, Goleva E, Bissonnette R, Bronova I, Bronoff AS, Richers BN, et al. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy. 2022;77(11):3388\u201397. https:\/\/doi.org\/10.1111\/all.15432.","journal-title":"Allergy"},{"issue":"5","key":"9606_CR141","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jaip.2023.03.020","volume":"11","author":"DYM Leung","year":"2023","unstructured":"Leung DYM, Bissonnette R, Kreimer S, Berdyshev E, Bafna S, Lyubchenko T, et al. Dupilumab inhibits vascular leakage of blood proteins into atopic dermatitis skin. J Allergy Clin Immunol Pract. 2023;11(5):1421\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2023.03.020.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"9606_CR142","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1165\/ajrcmb.26.3.4684","volume":"26","author":"N Carayol","year":"2002","unstructured":"Carayol N, Campbell A, Vachier I, Mainprice B, Bousquet J, Godard P, et al. Modulation of cadherin and catenins expression by tumor necrosis factor-alpha and dexamethasone in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2002;26(3):341\u20137. https:\/\/doi.org\/10.1165\/ajrcmb.26.3.4684.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"9606_CR143","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1165\/rcmb.2003-0056OC","volume":"30","author":"C Coraux","year":"2004","unstructured":"Coraux C, Kileztky C, Polette M, Hinnrasky J, Zahm JM, Devillier P, et al. Airway epithelial integrity is protected by a long-acting beta2-adrenergic receptor agonist. Am J Respir Cell Mol Biol. 2004;30(5):605\u201312. https:\/\/doi.org\/10.1165\/rcmb.2003-0056OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"11","key":"9606_CR144","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/cea.13253","volume":"48","author":"HKT Trinh","year":"2018","unstructured":"Trinh HKT, Pham DL, Choi Y, Kim HM, Kim SH, Park HS. Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2018;48(11):1464\u201373. https:\/\/doi.org\/10.1111\/cea.13253.","journal-title":"Clin Exp Allergy"},{"key":"9606_CR145","doi-asserted-by":"crossref","unstructured":"Allinne J, Scott G, Birchard D, et al. Broader impact of IL-4R\u03b1 blockade than IL-5 blockade on mediators of type 2 inflammation and lung pathology in a house dust mite-induced asthma mouse model[M]\/\/C93. Mechanisms of airway inflammation in asthma and COPD. American Thoracic Society, 2019;A5555\u2013A5555. https:\/\/doi.org\/10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A5555.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A5555"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09606-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-025-09606-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09606-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:28:22Z","timestamp":1770190102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-025-09606-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9606"],"URL":"https:\/\/doi.org\/10.1007\/s12026-025-09606-9","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"60"}}